Curcuma olie gebruikt in plaats van chemo geeft zelfde therapeutische effect in vergelijking in gebruik bij HAI - is Arteriële toediening, maar in vergelijking met TACE langere overlevingstijd en betere kwaliteit van leven. Artikel update 14 juni 2011
13 juni 2011:
Veel mensen vergeten dat TACE - Trans Arteriele Chemo Embolisatie een behandeling is die wel levensverlenging geeft maar zelden overall overleving. Toch kunnen andere middelen die levensduur significant verlengen. Zie o.a. onderstaande studie naar effect van curcuma olie i.p.v. chemo bij TACE.
13 augustus 2005: bron: Zhongguo Zhong Xi Yi Jie He Za Zhi. 2001 Mar;21(3):165-7.
Chinese onderzoekers deden onderzoek naar de effecten van curcuma olie in vergelijking met chemo bij HAI = Arteriële toediening en TACE = Trans Arteriële toediening bij primaire leverkanker. De resultaten zijn goed. In vergelijking met HAI was het therapeutische effect gelijk, bij TACE was het effect van gebruik van curcuma olie zelfs beduidend beter op mediane overleving en ziektevrije tijd dan bij chemo gebruik. De kwaliteit van leven en de bijwerkingen waren bij het gebruik van curcuma olie ook beduidend beter dan bij gebruik van chemo. Een zeer interessante studie o.i.
[A controlled clinical study between hepatic arterial infusion with embolized curcuma aromatic oil and chemical drugs in treating primary liver cancer]
[Article in Chinese]
Cheng JH, Chang G, Wu WY.
Guangdong Provincial Hospital of Traditional Chinese Medicine, Guangzhou 510120.
OBJECTIVE: To evaluate the effectiveness, toxicity and prospective application of hepatic arterial infusion (HAI) with Embolized Curcuma Aromatic oil (CAO) in treating primary liver cancer (PLC).
METHODS: In the treated group, 32 patients with PLC were treated by HAI with 1-3 ml of embolized CAO and oral administration of Chinese herbal medicine. In the control group, 32 patients with PLC were treated with transcatheter artery chemoembolization (TACE).
RESULTS: In the treated group, one patient attained complete remission (CR) and 13 partial remission (PR), the total effective rate being 43.75%. The level of alpha fetal protein (AFP) turned to normal range in 7 cases and decreased in other 7. In the control group, 10 obtained PR and the total effective rate being 31.25%, AFP level turned to normal in 5 and decreased in 2. There was no statistical significance between the two groups. The incidences of post-embolism syndrome, such as fever, abdominal pain and vomiting were similar between the two groups but no myelosuppression occurred in the treated group with significant difference (P < 0.01) as comparing with that in the control group. The mean survival time, median survival time, 1-, 2- and 3-year survival rate in the treated group was 11.5 months, 10 months, 37.5%, 13.3% and 6.9% respectively, while in the control group was 7.25 months, 6 months, 15.6%, 3.2% and 0 respectively. The treated group was better in mean survival time, median survival time and 1-year survival rate than that of the control group (P < 0.05).
CONCLUSION: HAI with embolized CAO showed a similar favorite effect in treating PLC as that of TACE, but superior than TACE with longer survival time and milder myelosuppression. PMID: 12577327 [PubMed - indexed for MEDLINE]
